Validation of a new strength measurement device for amyotrophic lateral sclerosis clinical trials

被引:29
|
作者
Andres, Patricia L. [1 ]
Skerry, Linda M. [1 ]
Munsat, Theodore L. [2 ]
Thornell, Brenda J. [1 ]
Szymonifka, Jackie [3 ]
Schoenfeld, David A. [3 ]
Cudkowicz, Merit E. [1 ]
机构
[1] Massachusetts Gen Hosp, Neurol Clin Trials Unit, Charlestown, MA 02129 USA
[2] Tufts Med Ctr, Dept Neurol, Boston, MA USA
[3] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
关键词
ALS; neuromuscular; outcomes measures; reliability; strength testing; VOLUNTARY ISOMETRIC CONTRACTION; NATURAL-HISTORY; ALSFRS-R; SURVIVAL;
D O I
10.1002/mus.22253
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Strength measures with reduced variability and higher sensitivity could improve efficiency in clinical trials of amyotrophic lateral sclerosis (ALS). The Accurate Test of Limb Isometric Strength (ATLIS) was developed to precisely and conveniently measure force in 12 muscle groups. In this study we evaluate the reliability and validity of the ATLIS testing protocol. Methods: Twenty healthy adults and 10 patients with ALS were tested twice by the same or by different evaluators to determine test-retest and interrater reliability. Twenty healthy adults were examined using ATLIS and a wellvalidated strength testing protocol (TQNE) to assess criterionbased validity. Results: Mean absolute variation between tests was 8.6%, and intraclass correlation coefficients for each muscle group were high (range 0.82-0.99). The Pearson correlation coefficient of mean ATLIS and TQNE scores was 0.90. A subject survey demonstrated high user acceptance of ATLIS. Conclusions: ATLIS is convenient for patients and evaluators, produces precise strength measurements, and is easily moved between examining rooms.
引用
收藏
页码:81 / 85
页数:5
相关论文
共 50 条
  • [1] Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials
    Govindarajan, Raghav
    Berry, James D.
    Paganoni, Sabrina
    Pulley, Michael T.
    Simmons, Zachary
    MUSCLE & NERVE, 2020, 62 (03) : 321 - 326
  • [2] Clinical trials in amyotrophic lateral sclerosis
    McDermott, Christopher J.
    CURRENT OPINION IN NEUROLOGY, 2019, 32 (05) : 758 - 763
  • [3] Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective
    Wong, Charis
    Stavrou, Maria
    Elliott, Elizabeth
    Gregory, Jenna M.
    Leigh, Nigel
    Pinto, Ashwin A.
    Williams, Timothy L.
    Chataway, Jeremy
    Swingler, Robert
    Parmar, Mahesh K. B.
    Stallard, Nigel
    Weir, Christopher J.
    Parker, Richard A.
    Chaouch, Amina
    Hamdalla, Hisham
    Ealing, John
    Gorrie, George
    Morrison, Ian
    Duncan, Callum
    Connelly, Peter
    Carod-Artal, Francisco Javier
    Davenport, Richard
    Reitboeck, Pablo Garcia
    Radunovic, Aleksandar
    Srinivasan, Venkataramanan
    Preston, Jenny
    Mehta, Arpan R.
    Leighton, Danielle
    Glasmacher, Stella
    Beswick, Emily
    Williamson, Jill
    Stenson, Amy
    Weaver, Christine
    Newton, Judith
    Lyle, Dawn
    Dakin, Rachel
    Macleod, Malcolm
    Pal, Suvankar
    Chandran, Siddharthan
    BRAIN COMMUNICATIONS, 2021, 3 (04)
  • [4] Progress, development, and challenges in amyotrophic lateral sclerosis clinical trials
    Ashhurst, Jasmine F.
    Tu, Sicong
    Timmins, Hannah C.
    Kiernan, Matthew C.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2022, 22 (11-12) : 905 - 913
  • [5] Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials
    Balendra, Rubika
    Jones, Ashley
    Jivraj, Naheed
    Steen, I. Nick
    Young, Carolyn A.
    Shaw, Pamela J.
    Turner, Martin R.
    Leigh, P. Nigel
    Al-Chalabi, Ammar
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (01): : 45 - 49
  • [6] Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
    Goyal, Namita A.
    Berry, James D.
    Windebank, Anthony
    Staff, Nathan P.
    Maragakis, Nicholas J.
    van den Berg, Leonard H.
    Genge, Angela
    Miller, Robert
    Baloh, Robert H.
    Kern, Ralph
    Gothelf, Yael
    Lebovits, Chaim
    Cudkowicz, Merit
    MUSCLE & NERVE, 2020, 62 (02) : 156 - 166
  • [7] Xaliproden in amyotrophic lateral sclerosis: early clinical trials
    Lacomblez, L
    Bensimon, G
    Douillet, P
    Doppler, V
    Salachas, F
    Meininger, V
    AMYOTROPHIC LATERAL SCLEROSIS, 2004, 5 (02): : 99 - 106
  • [8] Methodological Quality of Clinical Trials in Amyotrophic Lateral Sclerosis: A Systematic Review
    Pupillo, Elisabetta
    Al-Chalabi, Ammar
    Sassi, Serena
    Arippol, Emilio
    Tinti, Lorenzo
    Vitelli, Eugenio
    Copetti, Massimiliano
    Leone, Maurizio A.
    Bianchi, Elisa
    JOURNAL OF NEUROMUSCULAR DISEASES, 2024, 11 (04) : 749 - 765
  • [9] Innovating Clinical Trials for Amyotrophic Lateral Sclerosis Challenging the Established Order
    van Eijk, Ruben P. A.
    Nikolakopoulos, Stavros
    Roes, Kit C. B.
    Kendall, Lindsay
    Han, Steve S.
    Lavrov, Arseniy
    Epstein, Noam
    Kliest, Tessa
    de Jongh, Adriaan D.
    Westeneng, Henk-Jan
    Al-Chalabi, Ammar
    Van Damme, Philip
    Hardiman, Orla
    Shaw, Pamela J.
    McDermott, Christopher J.
    Eijkemans, Marinus J. C.
    van den Berg, Leonard H.
    NEUROLOGY, 2021, 97 (11) : 528 - 536
  • [10] Toward more efficient clinical trials for amyotrophic lateral sclerosis
    Cudkowicz, Merit E.
    Katz, Jon
    Moore, Dan H.
    O'neill, Gilmore
    Glass, Jonathan D.
    Mitsumoto, Hiroshi
    Appel, Stanley
    Ravina, Bernard
    Kieburtz, Karl
    Shoulson, Ira
    Kaufmann, Petra
    Khan, Jaffar
    Simpson, Ericka
    Shefner, Jeremy
    Levin, Bruce
    Cwik, Valerie
    Schoenfeld, David
    Aggarwal, Swati
    McDermott, Michael P.
    Miller, Robert G.
    AMYOTROPHIC LATERAL SCLEROSIS, 2010, 11 (03): : 259 - 265